Search

everythinglearnresearchcommunity

for

Search:↓

A potential update on the progress of pyrilutamide, a hair loss treatment; and if Kintor should stop their trials.

New hair loss treatments include Breezula, PP405, ET-02, KX-826, GT20029, VDPHL01, and CosmeRNA, with some showing promise in reactivating stem cells and reversing greying. Breezula and VDPHL01 are highlighted as potential add-ons or alternatives to current treatments like finasteride and minoxidil.

PP405 is being discussed as a potential new approach to hair loss by targeting follicle stem cells, suggesting a different mechanism from existing treatments like finasteride and minoxidil. However, there is skepticism about whether it will lead to meaningful long-term outcomes or follow the pattern of previous treatments that showed promise but lacked consistent results.

User shared 7-month hair loss progress pictures. They used Minoxidil 10% topical solution.

The user applied Kindor's KU, followed by a solution of Finasteride, Minoxidil, and Tretinoin for alopecia. They experienced no side effects from Kindor's KU.

KX-826 Max combines KX-826, Kopyrrol, and Kopexil as a potential alternative to minoxidil and finasteride for hair loss, but users express skepticism about its effectiveness and high cost. Some users believe traditional treatments like minoxidil, finasteride, and others are more reliable.

Discussion on hair loss treatments, focusing on pp405, with skepticism about its effectiveness and concerns about its association with the cosmetic industry. Users also mention treatments like Minoxidil and Finasteride.

The conversation discusses the potential updates on the pp405 trial for hair loss, with completion expected by December 2025. Participants express skepticism about new treatments, suggesting continued use of finasteride, while others hope for innovative solutions beyond current medications.

17M approaching Norwood 2, using topical minoxidil and considering finasteride, oral minoxidil, and pyrilutamide. Plans to study dermatology and possibly get a hair transplant at 25 if treatments don't work.

A 35-year-old started finasteride in 2014 for hair loss and maintained hair density for 7 years, occasionally using ketoconazole shampoo. Switched to dutasteride in 2022 due to increased hair fall, experimented with dosages, and found a combination with tamsulosin effective despite initial adverse reactions.

The conversation is about Kintor's announcement indicating continued hope for their product KX-826 as a treatment for Alopecia Androgenetica. Specific treatments mentioned are Minoxidil, Finasteride, and RU58841.

The conversation humorously discusses hair loss treatments, mentioning Minoxidil, finasteride, and RU58841. It suggests that affordable genetic therapy could be the ultimate solution.

PP405 is being discussed as a potential hair loss treatment, possibly more effective than minoxidil. There are concerns about its effectiveness and product contamination, but some users report early signs of hair regrowth.

Hair loss discussion involved Finasteride, Minoxidil, and RU58841. User experienced sudden shedding after 1.5 years of Finasteride and Minoxidil use, seeking advice.

A six month update of the users' experience with Pyrilutamide, a hair loss treatment that combines Minoxidil, Finasteride and RU58841.

People are discussing the potential of a new hair loss treatment, pp405, and its approval timeline, comparing it to existing treatments like Minoxidil and finasteride. There is skepticism about its effectiveness and concerns about the time it will take for approval and availability, especially in Europe.

Verteporfin human clinical trials for hair loss may start in 2025. Additional resources and presentations are available for more information.

KX-826 initially improves hair growth but declines after 24 weeks, with mild itching as a side effect. Combining it with minoxidil and finasteride may improve results, but long-term effectiveness is uncertain.

People are discussing the group buy and availability of KX-826 for hair loss treatment, with shipments expected around March-April. There is interest in finding more information and joining future group buys.

A user shared progress pictures showing improvement in PCOS-related hair loss after six months of using topical minoxidil, dermarolling 0.5mm weekly, and taking biotin gummies. They expressed happiness about the appearance of new baby hairs.

Kintor Pharma has started a Phase II trial in China for GT20029, a potential new treatment for hair loss. Participants are discussing the significance, potential release dates, and comparing it to other treatments and technologies like stem cell hair transplants and SAMIRNA.

KX-826 did not maintain hair loss prevention for users. Some switched to Pyrilutamide but returned to Minoxidil and RU58841 due to worsening conditions.

RU58841 treatment for hair loss, comparing premixed solutions to powder form. Users prefer powder for cost-effectiveness and customization.

Best future hair loss treatment discussed: verteporfin, kx-826, and GT20029. Verteporfin could potentially end baldness with scarless procedures.

Verteporfin shows promise in donor hair regeneration after 84 days. Combining Finasteride, Minoxidil, and Pyrilutamide with unlimited hair transplants is seen as a potential near-cure for hair loss.

A user shared a 7-month hair loss treatment progress using finasteride 1.25 mg, oral minoxidil 2.5 mg, ketoconazole shampoo, and monthly micro-needling, noting denser hair and improved quality but no significant regrowth. They experienced mild testicular discomfort and heart palpitations, considering switching to topical minoxidil to avoid side effects.

A clinical trial for Verteporfin as a hair loss treatment, and the potential for greater progress in treatments for hair loss in the future. Common treatments such as Minoxidil, Finasteride and RU58841 were discussed.

A 28-year-old male experiencing early male pattern baldness is considering using Pyrilutamide (KX-826) as an alternative to finasteride due to side effects. He seeks to maintain his current hair without regrowth and is concerned about potential side effects like reduced libido.

The conversation discusses the difference between the commercially available Pyrilutamide and the version in clinical trials. It also mentions treatments like Minoxidil, finasteride, and RU58841 for hair loss.

The conversation is about hair loss treatments, specifically Pyrludimide (KX-826) and Breezula (clascoterone), with the user unable to tolerate finasteride and dutasteride. The user plans to use these treatments alongside minoxidil, considering the efficacy and availability of each option.